Sanofi - ADR (SNY) Social Stream



Sanofi - ADR (SNY): $53.80

0.02 (+0.04%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About SNY

$MNKD $SNY $LLY $NVO

Another example of the superiority and excellence of Afrezza, the world’s ONLY ultra rapid acting insulin that mimics physiologic insulin and restores post-prandial glucose homeostasis.

🥭 Post hoc analysis of the STAT study shows that Technosphere® insulin reduced nocturnal hypoglycemia compared to insulin aspart in adult patients with T1D

🥭 With this post hoc statistical analysis, we divided the CGM data into day and night and showed that using Technosphere Insulin versus aspart reduced Level 1 nocturnal hypoglycemia by 62% and Level 2 by 78%

https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-announces-data-presentation-14th-international
mango3, published June 3, 2021

What Else are SNY Traders Talking About?


Other tickers frequently mentioned alongside SNY are PFE, MNKD, LLY and NVO.

Other Notable StockTweets About SNY


$BNTX Most of this week's news til yesterday was anticipated, and thus likely priced in. Today, however, there was an accumulation of slightly concerning news. 1) $PFE indemnity issue with India, 2) EU persuaded US to ease restrictions on $CVAC sourcing - supply isssue til August resolved with Curevac being a close competitor of Biontech. 3) $BNTX $PFE promiss 2 billion vaccines for poorer countries at rather low or no profit margin. 4) According to an EU commissioner, the new EU order signed yesterday contains delivery deadlines and penalties which adds pressure on $BNTX. 5) There may be a serious mid-term threat from $CVAC, on the one hand and $SNY / $GSK on the other hand, which is well summarized in this German article published this morning. .https://www.finanznachrichten.de/nachrichten-2021-05/52938495-biontech-in-die-zange-genommen-sanofi-gsk-s-spike-vakzin-und-curevac-gsk-s-mrna-der-2-generation-617.htm The pro news is: $BNTX has a rather lean cost structure with mainly the €600m research in 2020 yet to be funded. But for a $200 valuation, revenues need to be at least $60bn over the coming 18 months.

Tbird96, published May 21, 2021

$OCGN $PFE $MRNA $SNY $NVAX DOESNT MATTER WHICH VACCINES COMPANY YOU SUPPORT. OUR PRIORITIES IS TO SAVE THE WORLD AND BUILD OUR PORTFOLIOS.

HATE IT WHEN BEARS AND SHORTERS MANIPULATE BY SHARING FAKE NEWS. THIS IS INDEED LOW CLASS JOB..

LogicalBullPush, published May 17, 2021

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5588 seconds.